Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has announced it has sent letters to shareholders who have not registered their email IDs. These letters provide a web-link to the company's Integrated Annual Report for the Financial Year 2025-26. This action is taken pursuant to Regulation 36(1)(b) of SEBI Listing Regulations, ensuring compliance with disclosure requirements. For investors, this update highlights the company's commitment to transparent communication and facilitating access to important financial information for all shareholders. No new financial figures or strategic decisions were announced in this procedural update.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has released its Business Responsibility and Sustainability Report for the Financial Year 2025-26, as per Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 10, 2026. The meeting will consider and adopt the audited standalone and consolidated financial statements for the financial year ended on March 31, 2026, and the reports of the Board of Directors and Auditors. The meeting will also consider the re-appointment of Mr. Sanjay Sinha as Director, ratify the remuneration of Cost Auditors, and approve the revision in remuneration of Mr. Sanjeev Jain, Managing Director and Promoter.